Financhill
Back

NLS Pharmaceutics Quote, Financials, Valuation and Earnings

NLS Pharmaceutics Price Quote

$3.84
-0.13 (-3.27%)
(Updated: November 12, 2024 at 5:55 PM ET)

NLS Pharmaceutics Key Stats

Sell
30
NLS Pharmaceutics (NLSP) is a Sell

Day range:
$3.68 - $4.01
52-week range:
$3.51 - $29.08
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%

Volume:
116.7K
Avg. volume:
421.3K
1-year change:
-84.49%
Market cap:
$15.1M
Revenue:
$0
EPS:
$-6.74

How Much Does NLS Pharmaceutics Make?

Data Unavailable

Is NLS Pharmaceutics Growing As A Company?

Data Unavailable

NLS Pharmaceutics Stock Price Performance

  • Did NLS Pharmaceutics Stock Go Up Last Month?
    NLS Pharmaceutics share price went down by -10.79% last month
  • Did NLSP's Share Price Rise Over The Last Year?
    NLSP share price fell by -84.49% over the past 1 year

What Is NLS Pharmaceutics 52-Week High & Low?

NLS Pharmaceutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy NLS Pharmaceutics?

  • How Much Debt Does NLS Pharmaceutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does NLS Pharmaceutics Have?
    Cash and short term investments quarterly total is $552.8K
  • What Is NLS Pharmaceutics’s Book Value Per Share?
    Book value per share is -9.40

Is NLS Pharmaceutics Cash Flow Positive?

  • What Is NLSP Cash Flow From Operations?
    Cash flow from operations (TTM) is -$3.9M
  • What Is NLS Pharmaceutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2.8M
  • What Is NLS Pharmaceutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

NLS Pharmaceutics Return On Invested Capital

Data Unavailable

NLS Pharmaceutics Earnings Date & Stock Price

NLS Pharmaceutics Competitors

  • Who Are NLS Pharmaceutics's Competitors?
    Below is a list of companies who compete with NLS Pharmaceutics or are related in some way:
    • AC Immune SA (ACIU)
    • Addex Therapeutics Ltd (ADXN)
    • CRISPR Therapeutics AG (CRSP)
    • MoonLake Immunotherapeutics (MLTX)
    • Molecular Partners AG (MOLN)

NLS Pharmaceutics Dividend Yield

NLS Pharmaceutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 240.00
Upside from Last Price: 5945.34%

Major Shareholders

  • How many NLSP shares are owned by institutional investors?
    275.3K NLSP shares are owned by institutional investors
  • How many NLSP shares are owned by insiders?
    0 NLSP shares are owned by insiders